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Abstract
Background: Tuberculosis (TB) patients have difficulty following a long-term treatment regimen.
Efforts to improve treatment outcomes require better understanding of adherence as a complex
behavioral issue and of the particular barriers to and facilitators of patient adherence.
Methods: This study was carried out in Jiangsu Province of China with both quantitative and
qualitative approaches. For the quantitative study, 780 sputum-smear positive TB patients
consecutively registered since 2006 in 13 counties (districts) were queried with a structured
questionnaire. Patients who had missed 10% of their total prescribed doses of TB drugs were
deemed as non-adherent. Risks for non-adherence were estimated by computing odds ratios (ORs)
and their 95% confidence intervals (95% CIs) using a logistic regression model. We also invited 20
TB patients and 10 local health workers for in-depth interviews. We then used content analysis
based on this qualitative study to explore factors associated with non-adherence.
Results: The proportion of non-adherence among 670 patients was 12.2%. Univariate analysis
showed that patients, who were illiterate, divorced/widowed, lacked health insurance and were
migrants, were more likely to be non-adherent. The crude ORs(95%CIs) were 2.38(1.37-4.13),
2.42(1.30-4.52), 1.89(1.07-3.32) and 1.98(1.03-3.83), respectively. The risk of non-adherence was
lower among patients whose treatment was given under direct observation by village doctors or
regular home visits by health workers, with ORs (95% CIs) of 0.19(0.10-0.36) and 0.23(0.10-0.51),
respectively. In multivariate analysis, factors associated with non-adherence included illiteracy (OR:
2.42; 95% CI: 1.25-4.67) and direct observation by village doctors (OR: 0.23; 95% CI: 0.11-0.45).
The in-depth interviews indicated that financial burdens and extra medical expenditures, adverse
drug reactions, and social stigma were additional potential factors accounted for non-adherence.
Conclusion: More importance should be given to treatment adherence under the current TB
control program. Heavy financial burdens, lack of social support, adverse drug reactions and
personal factors are associated with non-adherence. Direct observation and regular home visits by
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health workers appear to reduce the risk of non-adherence. More patient-centered interventions
and greater attention to structural barriers are needed to improve treatment adherence.
Background
Despite the recent progress of global efforts, tuberculosis
(TB) is still one of the leading causes of morbidity and
mortality world-wide, and remains as a major public
health burden in many developing countries [1]. Current
anti-tuberculosis therapy consists of a cocktail of drugs
taken over a period of at least 6 months for new patients
and 8 months for retreatment patients. Because of the
long duration of the therapy, there is a risk of treatment
interruption or default, a phenomenon that contributes to
prolonged infectiousness, drug resistance, relapse and
death [2,3]. The difficulty experienced by patients in fol-
lowing treatment regimens has raised the awareness of
adherence as a complex behavioral issue [4]. Efforts to
improve treatment outcomes require a better understand-
ing of particular barriers to and facilitators of patient's
adherence [5].
Studies of socioeconomic and behavioral factors affecting
adherence have been conducted previously [6-9]. In Hong
Kong, China, a study of 102 defaulters matched to 306
controls indicated that tobacco smoking, a history of prior
treatment default or poor adherence, treatment side
effects, and subsequent hospitalization were associated
with treatment default [10]. A study in Fujian, China, that
combined quantitative and qualitative methods reported
that treatment adherence was associated with the inten-
tion of patients and the behavior of health service provid-
ers, but not with gender, age, career, education level or
social stigma [11]. Another study in Chongqing, China,
which involved interviewing patients and health staff,
indicated that additional tests and drugs, especially liver
protection drugs, may entail considerable financial barri-
ers to starting and continuing treatment [7]. However,
these aspects of treatment adherence have not been stud-
ied previously in Jiangsu Province of China. Therefore, to
identify the social context, patient characteristics, and
health system factors affecting patient's adherence to anti-
tuberculosis treatment in Jiangsu Province, we conducted
a study using both qualitative and quantitative methods.
Our goal was to provide policy-makers with recommen-
dation for more organized TB control program to improve
the adherence to anti-tuberculosis treatment.
Methods
Study sites
This study was carried out in Jiangsu Province, which is
located along the eastern coast of China and covers an
area of 102.6 thousand square kilometers, about 1% of
the total area of the country. Jiangsu Province contains 13
municipalities and 106 counties (districts), with a total
population of 74 million. The population density is 736
per square kilometer, the highest among all provinces of
China. The annual net per capita income of farmers in
Jiangsu Province is 6561 Yuan ($964), and the annual
employee salary is 27234 Yuan ($4005). The average life
expectancy of the local population is 75.3 years, with men
at 72.9 and women at 77.9 years, respectively. DOTS
(direct observed therapy, short course) strategy for TB was
introduced in the 1990s and is now 100% available at the
county level. An internet-based surveillance system was
set up in 2004, and all newly diagnosed TB cases are
required to be registered with the local TB dispensary and
reported to upper level health authorities.
Data collection
This study was designed to use both quantitative and
qualitative methods in order to gain insights into the fac-
tors that could contribute to adherence. A multi-stage
sampling strategy was implemented for the quantitative
aspects of the study. We selected 13 municipalities as the
first sampling unit. In each municipality, one county (dis-
trict) was randomly selected as the study site. In each site,
60 sputum-smear-positive TB patients registered since
2006 were consecutively selected as study subjects. The
total estimated sample size was 780, given a confidence
interval = 95%, an estimated non-adherent proportion =
20%, a relative precision = 0.2P, design efficiency = 2, and
the number of study sites = 13. After obtaining informed
consent, trained local TB dispensary staff interviewed all
participants with a structured questionnaire, including
basic characteristics, socioeconomic status, treatment his-
tory and adherence to anti-tuberculosis treatment. Non-
adherent patients were further presented with 16 options
for reasons of their non-adherence. In this study, observed
treatment was divided into four categories: self-adminis-
tered (patient took drugs without external observation);
observed by family members or others (patient took drugs
under the observation by family members or other volun-
teers); home-based drug delivery (local health workers
sent anti-tuberculosis drugs to patients' home regularly,
but did not observe them taking each dose of drugs); and
directly observed by village doctors (patients took drugs
under the direct observation by village doctors each time).
For the qualitative study, 20 TB patients (from Xuanwu
and Taichang, 15 men, 5 women; 18 newly treated, 2 pre-
viously treated) were invited for in-depth interviews based
on a convenience sampling strategy. A semi-schematized
guide covering general as well as specific questions wasBMC Health Services Research 2009, 9:169 http://www.biomedcentral.com/1472-6963/9/169
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utilized. The in-depth interview focused on patients'
health-care seeking history, knowledge and attitudes
towards TB, and their adherence to TB treatment. Ten
local health workers from Taichang, including 5 village
doctors and 5 community hospital doctors, were also
invited for in-depth interviews. Themes for the in-depth
interviews with these doctors included the current TB con-
trol program in the village/community, the main prob-
lems with and suggestions for the current TB program,
treatment adherence of patients in the corresponding vil-
lage/community, and the main reasons for non-adher-
ence. Interviews were conducted in local health facilities
by trained professionals from Jiangsu Provincial Center
for Disease Prevention and Control with Chinese Manda-
rin. They lasted 20-40 minutes and were tape-recorded
with permission.
Data analysis
In this study, patients who had missed 10% or more of the
total prescribed dose of TB drugs were deemed as non-
adherent. For the quantitative study, data were entered in
Epidata (Denmark) and analyzed using STATA 10.0 (Col-
lege Station, TX, USA). Associations between selected fac-
tors and non-adherence were estimated by computing
odds ratios (ORs) and their 95% confidence intervals
(CIs) from an unconditional logistic regression model.
Predictive variables that were independently significantly
associated with treatment completion in univariate analy-
sis were included in a multiple logistic regression model
to determine their relative contributions in predicting
treatment adherence while simultaneously adjusting for
each of their effects. The criterion for significance was set
at P < 0.05 based on a two-sided test. Continuous varia-
bles, including age and income, were converted to dichot-
omous variables using the median as the cutoff point.
For the qualitative study, content analysis was applied
[12,13]. Tape-recorded in-depth interviews were firstly
transcribed in Chinese characters and then translated into
English by two trained staffs in the Jiangsu Provincial
Center for Disease Prevention and Control. Codes were
then developed based on the original terms used by par-
ticipants. The transcripts and notes were analyzed themat-
ically by categorizing the interview data under the main
topic headings. The codes were then presented, discussed
and checked within the research team. Tentative catego-
ries and sub-categories were created from the clustered
codes, and subsequently main themes emerged based on
the patterns and relationship between the categories.
Ethical consideration
This study was approved by Ethics Committee in Center
for Disease Control and Prevention. Oral informed con-
sent was obtained from all participants.
Results
Findings from the quantitative study
A total of 670 patients were successfully enrolled and
investigated in the study, with a response rate of 85.9%.
The main reasons for loss to follow up were migration,
unemployment, address or telephone number change,
death and refusal to join the study. We compared some of
the key characteristics of the 670 TB patients included in
the analyses with those of 110 patients lost to follow up,
and we found little difference in gender (73.4% and
73.0% were men, respectively) or age (51.4 years vs. 49.4
years, respectively). The average age (± s.d.) of study sub-
jects was 51.4 ± 19.5 years old (men: 53.9 ± 18.9; women:
44.4 ± 19.5). Of these, 578 (86.3%) were new patients
and 92 (13.7%) were retreated. The non-adherent propor-
tion overall was 12.2% (82/670), which was similar
between new patients and previously treated patients
(12.6% vs. 9.8%). Approximately half of non-adherent
patients interrupted their treatment intermittently
(missed a total of more than 10% of all doses) and 41
stopped treatment before receiving 90% of their pre-
scribed course. As shown in table 1, only 47.8% were
treated with direct observation by village doctors and
16.9% took drugs without external supervision. Univari-
ate analysis showed that patients, who were illiterate,
divorced/widowed, lacked health insurance or were
migrants, were more likely to be non-adherent. The crude
ORs (95%CIs) were 2.38(1.37-4.13), 2.42(1.30-4.52),
1.89(1.07-3.32) and 1.98(1.03-3.83), respectively. The
risk of non-adherence was lower among patients whose
treatment was given under direct observation by village
doctors or home visits by health workers, with
ORs(95%CIs) of 0.19(0.10-0.36) and 0.23(0.10-0.51),
respectively. In multivariate analysis, factors associated
with non-adherence included illiteracy (OR: 2.42; 95%
CI: 1.25-4.67) and direct observation by village doctors
(OR: 0.23; 95% CI: 0.11-0.45) (table 2). The main reasons
for non-adherence listed by patients (table 3) were
adverse reactions to anti-tuberculosis drugs (37.8%),
relieved symptoms (26.8%), long course regimen and
large dose of drugs (15.9%), worry about dangers of drugs
(15.9%), other disorders (15.9%), financial burden and
medical expenditures (15.9%).
Findings from the qualitative study
A total of 19 patients (95%) and 9 doctors (90%) were
successfully interviewed. The main findings from the in-
depth interviews are as follows:
(1) TB services are not actually free
Under the current "free service policy", patients report
that they still need to pay extra fees for medical examina-
tions, hospitalizations, and liver protection drugs. The
additional cost is regarded as an important issue related toBMC Health Services Research 2009, 9:169 http://www.biomedcentral.com/1472-6963/9/169
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treatment adherence and varies from hundreds to thou-
sands of Yuan per month. This sum accounts for a large
part of the usual family income (the annual net capita
income of farmers was 6561 Yuan and the annual
employee's salary was 27234 Yuan in 2007). Drugs
thought to protect the liver are frequently prescribed as
part of treatment for TB and are major contributors to
overall costs. These supposed liver protection drugs
include herbal preparations, finished manufactured
herbal products, combinations of vitamins and other
non-herbal substances, and pharmaceutical preparations,
most of which are not free of charge under the current
"free service policy". The larger and more specialized
health facility that patients visit, the higher the cost of the
liver protection drugs is. Patients treated in urban special-
ized TB dispensaries are usually recommended by their
doctors to be hospitalized, a process that entails much
more cost than being treated at rural dispensaries.
"My spouse newly passed away and I also lost my job. To sur-
vive, I have to take drugs. Though anti-tuberculosis drugs are
free of charge, other medical tests and liver protection drugs still
cost me up to 2,000 Yuan. It is a heavy burden on me."
(Patient)
Free anti-tuberculosis drugs provided by the local govern-
ment are limited to the specified brands. Many patients
complain about adverse reactions and the low quality of
these drugs. Although it is only hearsay that free drugs are
worse than privately purchased drugs, such information is
widespread among patients in many sites. Local doctors
also admitted that they sometimes recommend to
patients, especially those who are old and weak, that they
buy drugs rather than use the freely provided drugs.
Patients with drug resistant infections, especially those
with multi-drug resistant TB, face much greater difficulties
since the second line anti-tuberculosis drugs are not free
Table 1: Univariate analysis of association between selected factors and treatment adherence
Variables Total Adherent OR(95% CI) P value
n Yes, n(%) No, n(%)
Gender
Men 492 434(88.21) 58(11.79) 1.00
Women 178 154(86.52) 24(13.48) 1.17(0.70-1.94) 0.555
Age (years)
<53 326 292(89.57) 34(10.43) 1.00
≥53 344 296(86.05) 48(13.95) 1.39(0.87-2.22) 0.165
Education
Junior high school or over 325 295(90.77) 30(9.23) 1.00
Elementary school 196 173(88.27) 23(11.73) 1.31(0.74-2.32) 0.361
Illiterate 149 120(80.54) 29(19.46) 2.38(1.37-4.13) 0.002
Marital status
Married 495 441(89.09) 54(10.91) 1.00
Unmarried 105 93(88.57) 12(11.43) 1.05(0.54-2.05) 0.877
Divorced/widowed 70 54(77.14) 16(22.86) 2.42(1.30-4.52) 0.006
Family monthly income per capita (Yuan)
<450 328 288(87.80) 40(12.20) 1.00
≥450 342 300(87.72) 42(12.28) 1.01(0.63-1.60) 0.973
Health insurance
Yes 570 507(88.95) 63(11.05) 1.00
No 100 81(81.00) 19(19.00) 1.89(1.07-3.32) 0.027
Residence status
Permanent residents 606 537(88.61) 69(11.39) 1.00
Migrants 64 51(79.69) 13(20.31) 1.98(1.03-3.83) 0.041
Treatment history
Newly treated 578 505(87.37) 73(12.63) 1.00
Retreated 92 83(90.22) 9(9.78) 0.75(0.36-1.56) 0.440
Observed treatment
Self-administered 113 86(76.11) 27(23.89) 1.00
Observed by family members or others 117 95(81.20) 22(18.80) 0.74(0.39-1.39) 0.347
Home-based drug delivery 120 105(87.50) 15(12.50) 0.46(0.23-0.91) 0.026
Directly observed by village doctors 320 302(94.38) 18(5.63) 0.19(0.10-0.36) < 0.001
Regular home-visiting by health workers
No 28 18(64.29) 10(35.71) 1.00
Yes 642 570(88.79) 72(11.21) 0.23(0.10-0.51) < 0.001BMC Health Services Research 2009, 9:169 http://www.biomedcentral.com/1472-6963/9/169
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under the current national TB program. Both patients and
local doctors reported that treatment is sometimes discon-
tinued because of the higher financial burden of these
drugs.
"When I was hospitalized, the doctor asked me to make a choice
between free drugs and private expense ones. I knew nothing
about their difference. The doctor recommended me to buy pri-
vate expense drugs instead of using free ones, because the latter
are worse. Afterward, other doctors told me the truth that both
are the same. It cost me more than 10,000 Yuan for the first
month treatment." (Patient)
"One patient aged 30 years old, coming from Shanxi Province,
had good adherence at the first stage. However, after five
months of treatment, the sputum smear test was still positive. I
recommended him to do drug susceptibility test. Unfortunately,
he was defined as a multi-drug resistant patient. Doctors in
Shanghai Pulmonary Hospital recommended him to be hospi-
talized for standard treatment. Finally he gave up as the esti-
Table 2: Multiple logistic regression model to determine the factors predicting treatment non-adherence
Variables OR(95% CI) P value
Education
Junior high school or over 1.00
Elementary school 1.32(0.70-2.50) 0.392
Illiterate 2.42(1.25-4.67) 0.008
Marital status
Married 1.00
Unmarried 1.18(0.56-2.51) 0.661
Divorced/widowed 1.84(0.93-3.64) 0.080
Health insurance
Yes 1.00
No 1.48(0.70-3.14) 0.308
Residence status
Permanent residents 1.00
Migrants 1.34(0.56-3.20) 0.508
Observed treatment
Self-administered 1.00
Observed by family members or others 0.76(0.38-1.50) 0.426
Home-based drug delivery 0.52(0.25-1.10) 0.086
Directly observed by village doctors 0.23(0.11-0.45) < 0.001
Regular home-visiting by health workers
No 1.00
Yes 0.45(0.18-1.11) 0.083
Table 3: Factors associated with non-adherence listed by patients
Reasons for non-adherence n* %
1. Symptoms have been relieved and it is not necessary to continue treatment 22 26.83
2. Disease conditions have not been alleviated after treatment and the drugs seem to be ineffective 6 7.32
3. Treatment is not necessary as I am so old 7 8.54
4. I am working busy 5 6.10
5. Treatment course is too long and the dose is too large 13 15.85
6. I always forget to take drugs 11 13.41
7. Adverse drug reactions are severe 31 37.80
8. I worry about my body damaged by anti-tuberculosis drugs 13 15.85
9. Appetite is influenced after taking drugs 8 9.76
10. Other diseases cause interruption 13 15.85
11. Migration 8 9.76
12. Following doctor's advices 91 0 . 9 8
13. Following other's suggestions 4 4.88
14. I am not satisfied with health-care services 2 2.44
15. Financial difficulty and higher medical cost 13 15.85
16. Other reasons 19 23.17
*: Total number of non-adherent patients = 82BMC Health Services Research 2009, 9:169 http://www.biomedcentral.com/1472-6963/9/169
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mated cost was up to 10,000 Yuan. Can you imagine that his
whole income per month was only 1,000 Yuan? The only thing
he could do was giving up the treatment." (Doctor)
(2) Adverse reactions
In-depth interviews among both TB patients and local
doctors indicate that adverse drug reaction is a reason for
treatment non-adherence. Fear of the risks of adverse drug
reactions leads some TB patients to interrupt treatment.
Local health workers often cannot detect this discontinu-
ation of treatment due to the lack of an active adverse drug
reaction surveillance system under the current DOTS pro-
gram.
"The majority of TB patients in my village have good adherence
to treatment. However, some patients are reluctant to cooperate
with us. The main reasons are the adverse reactions and long
course of treatment. For example, one patient didn't visit my
clinic to take drugs as regularly. So I called him immediately.
He told me that he didn't want to continue as he felt much
more uncomfortable after taking drugs." (Doctor)
(3) Stigma
A stigma attached to TB in China can lead to imposition
of socio-physical distance and participatory restrictions
on those suffering from the disease. The stigmatizing atti-
tudes and behaviors of the community members towards
the disease and its sufferers may lead individuals with TB
to hide the diagnosis from others and to default from
treatment. Although the National TB Program recom-
mends that patients be treated under direct observation,
some patients prefer to take their drugs at home without
supervision. One reason that they do this is to conceal the
disease from others due to fear of being discriminated
against and isolated. Patients who are employed risk
being fired if the employer knows they have TB. Unem-
ployment, and the high cost of disease, can put heavy
financial burdens on the family and lead patients to termi-
nate treatment. Some migrant workers with TB have to
move because they are driven out by their landlords or
dismissed from their factories after being diagnosed.
Because of this, patients would like to keep their names
and addresses secret, which make it difficult for local
health workers to visit and follow them. This situation is
much worse among migrant patients.
"I lost my job after being diagnosed with TB. Without income,
I can't afford the treatment. Moreover, my daughter needs
money to pay for the tuition fee and I need to repay the debt for
my newly built house. Now I have owed the hospital hundreds
of Yuan." (Patient)
"Nonlocal patients change phone numbers frequently.
Addresses they present usually are inaccurate on purpose, which
makes it difficult to follow. I think one of the main reasons is
that they are afraid of stigma and losing job." (Doctor)
Discussion
Early detection of patients and providing effective treat-
ment are the main interventions to prevent the spread of
TB. However, current long-term anti-tuberculosis therapy
could easily lead to patient non-adherence, which
presents an important barrier for TB control programs
[8,14]. Patients' adherence to their medication regimens
has been reported to be influenced by the interaction of
number of factors [8]. These various factors may be
grouped as: health-system factors, social and family fac-
tors, and personal factors [15]. The factors that influence
patient adherence to TB treatment vary in different popu-
lations, and those that emerged in our current study might
be similar to, or different from, those reported in other
areas of China.
The financial burden on TB patients was one of the key
issues we found to be associated with non-adherence in
our study. Although the government of China has estab-
lished a "free TB service policy" with the aim of decreasing
the financial burden on patients, this free policy seems to
be not as well known or well implemented as planned in
some areas [12,16]. In a previously reported study in four
provinces of China [17], TB patients were obliged to pay
12-40% of their annual income for TB services, despite the
fact that all smear-positive and some severe smear-nega-
tive patients received free drugs. It is believed that the
heavy financial burden on patients is one of the main rea-
sons that some TB patients fail to access and complete the
treatment. The main financial burdens, as evidenced in
the present study, are the extra cost for medical examina-
tions, the need to purchase liver protection drugs, and
hospitalization costs.
Conflicts of interest may be an underlying reason for the
existence of heavy financial burdens on patients in the
presence of the free treatment policy. Briefly, with the
transformation from a traditional planned economy to a
market-oriented economy beginning in the early 1980s, a
larger part of rural health facilities in China were either
totally or partially privatized [18]. These rural facilities
have developed a variety of means to attract patients, in an
effort to generate more revenues by providing more clini-
cal services and selling more drugs [18]. Even in the state-
owned hospitals, a fee for service and bonus-related reve-
nue system has been adopted to encourage medical staff
to make more money, a process that can increase the eco-
nomic burden on patients, elevate health-care costs, and
ultimately impede effective TB control in China.
Drugs are frequently prescribed in some countries, and
especially in China, to protect the liver during treatment
for TB [19]. A systematic review based on 85 research arti-
cles, which evaluated 30 distinct types of putative liver
protection compounds, found no reliable evidence to
support prescription of drugs or herbs for this purpose toBMC Health Services Research 2009, 9:169 http://www.biomedcentral.com/1472-6963/9/169
Page 7 of 8
(page number not for citation purposes)
people on TB treatment [19]. However, a variety of pre-
sumed liver protection drugs are still widely used in China
and their purchase accounts for a large part of patients'
medical expenditures. On one hand, doctors prescribe
these drugs with the hope that they will prevent hepatic
injury induced by anti-tuberculosis treatment. On the
other hand, doctors generate more revenue by selling
these drugs, as liver protection drugs are not freely pro-
vided under the current TB program. To quote one doctor
in our study, "if we only deliver free anti-tuberculosis
drugs rather than selling private expense drugs to patients,
how can we get the bonus?"
Adverse reactions to current TB treatment, including
hepatic injury, also contribute to non-adherence, as has
been described in numbers of studies [8]. Xia reviewed
reports published on this topic between 1996-2005 in
China and found that the overall incidence of anti-tuber-
culosis drug induced adverse reactions was 12.6%, with
hepatic injury the most common one (mean = 11.90%,
median = 15.66%, range 0.75%-71.43%) [20]. In our
present study, adverse drug reaction to TB treatment was
also listed by patients as the most common factor (37.8%)
associated with non-adherence. Thus, active surveillance
of patients' adverse reactions would be far preferable to
merely prescribing possibly ineffective liver protection
drugs. To minimize the impact of adverse reactions, it is
important that health staff provide concise pretreatment
counseling to patients and that they manage such side-
effects with timely recommendations and services [21].
TB was originally named "Phthisis" and regarded as a
deadly disease in China. With the development of mod-
ern medicine, TB is no longer an incurable disease. How-
ever, TB patients still experience stigma and are always
isolated from the community. Although the Chinese gov-
ernment has carried out massive education programs in
recent years, knowledge of TB among the general popula-
tion is still limited [16]. Social support can help patients
overcome structural barriers as well as personal barriers,
and community and family members' attitudes may influ-
ence a patient's decision whether to stop or continue TB
treatment. In such circumstances, community-based TB
treatment programs and stronger involvement of local
social networks to support TB patients may be justified
[6].
Direct observation of treatment (DOT) has been recom-
mended by WHO to enhance patients' adherence and is
regarded as a main component of the "breakthrough" in
TB control programs [22]. However, DOT is not imple-
mented as well as expected in some areas of China
[7,23,24]. A study in Chongqing reported that less than
5% of TB patients had been treated under direct observa-
tion by health staff, and 12.5% of patients reported "inter-
rupted treatment" [7]. In Shandong Province, only 21% of
patients took their medicine under the surveillance of vil-
lage doctors, and this proportion varied widely across the
counties, from 0% to 70% [23]. Our findings from this
study also proved that DOT is not well accepted in some
rural areas of Jiangsu. Other alternatives need to be stud-
ied as possible ways to reinforce adherence in patients
who do not accept direct observation treatment in village
clinics. In Jiangsu Province, patients usually visit the TB
dispensary monthly and get the anti-tuberculosis drugs
for the whole month. They swallow the drugs under the
direct observation by doctors or family members or super-
vise by themselves. Due to different reasons, some
patients might not attend the regular visits to TB dispen-
sary, resulting in the interruption of treatment. In such a
case, local health workers are responsible for delivering
drugs to patients' home and perform patient retrieval.
Strictly, it is not a real direct observation because health
workers don't observe patients swallowing each dose of
drugs. But it is still believed to be an alternative way to
help increase the adherence, given that DOT is not
accepted by the patient. A centerpiece of the DOTS strat-
egy is that it shifts responsibility for completion of therapy
and successful clinical outcomes to the healthcare pro-
vider rather than to the patients themselves [25]. It is clear
that good health services are necessary, but not sufficient,
to ensure treatment success [15]. Patients still need to
choose to take drugs. Building supportive patient-doctor
relationships, rather than solely relying on authoritarian
supervision, can best improve treatment adherence and
TB control [26].
Several methodological issues should be discussed.
Firstly, results of this study come from Jiangsu Province
and may not represent the conditions in all of China. Sec-
ondly, 14.1% of selected subjects could not be traced and
were not involved in the analysis, raising the possibility of
some selection bias. Thirdly, data on treatment history
and possible explanatory factors in this study were based
on self-report of patients. Recall bias and investigator bias
were thus unavoidable.
Conclusion
More importance should be given to treatment adherence
under the current TB control program. Heavy financial
burdens, lack of social support, adverse drug reactions and
personal factors are associated with non-adherence. Direct
observation and regular home visits by health workers
appear to reduce the risk of non-adherence. More patient-
centered interventions and greater attention to structural
barriers are needed to improve treatment adherence.Publish with BioMed Central    and   every 
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